This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Odds, F. C.
Right arrow Articles by Warnock, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odds, F. C.
Right arrow Articles by Warnock, D. W.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2004, p. 3475-3482, Vol. 42, No. 8
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.8.3475-3482.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

Frank C. Odds,1* Mary Motyl,2 Roberto Andrade,3 Jacques Bille,4 Emilia Cantón,5 Manuel Cuenca-Estrella,6 Amanda Davidson,1 Christian Durussel,4 David Ellis,7 Elyse Foraker,8 Annette W. Fothergill,9 Mahmoud A. Ghannoum,10 Robert A. Giacobbe,2 Miguel Gobernado,5 Rosemary Handke,7 Michel Laverdière,11 Wendy Lee-Yang,12 William G. Merz,13 Luis Ostrosky-Zeichner,3 Javier Pemán,5 Sophia Perea,13 John R. Perfect,14 Michael A. Pfaller,15 Laurie Proia,16 John H. Rex,3,{dagger} Michael G. Rinaldi,9 Juan-Luis Rodriguez-Tudela,6 Wiley A. Schell,14 Christine Shields,13 Deanna A. Sutton,9 Paul E. Verweij,17 and David W. Warnock12

Aberdeen Fungal Group, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, United Kingdom,1 Merck Research Laboratories, Whitehouse Station, New Jersey,2 University of Texas-Houston Medical School, Houston, Texas 77030,3 Clinical Microbiology Laboratory, University Hospital, 1011 Lausanne, Switzerland,4 Service of Microbiology, University Hospital La Fe, 46009 Valencia,5 National Centre for Microbiology, Instituto de Salud Carlos III, 28220 Majadahonda, Spain,6 Mycology Unit, Women's and Children's Hospital, Adelaide, Australia,7 Infectious Disease Laboratory, Christiana Care Health Services, Wilmington, Delaware 19801,8 Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900,9 Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, Ohio 44106-5028,10 Department of Microbiology-Infectious Diseases, Hopital Maisonneuve- Rosemont, Montréal, Quebec H1T 2M4, Canada,11 Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333,12 The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-7093,13 Duke University Medical Center, Durham, North Carolina 27710,14 Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242,15 Section of Infectious Diseases, Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612,16 Medical Microbiology, UMC St. Radboud, 6500 HB Nijmegen, The Netherlands,17

Received 5 November 2003/ Returned for modification 12 January 2004/ Accepted 7 May 2004


arrow
ABSTRACT
 
Seventeen laboratories participated in a study of interlaboratory reproducibility with caspofungin microdilution susceptibility testing against panels comprising 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. The laboratories used materials supplied from a single source to determine the influence of growth medium (RPMI 1640 with or without glucose additions and antibiotic medium 3 [AM3]), the same incubation times (24 h and 48 h), and the same end point definition (partial or complete inhibition of growth) for the MIC of caspofungin. All tests were run in duplicate, and end points were determined both spectrophotometrically and visually. The results from almost all of the laboratories for quality control and reference Candida and Aspergillus isolates tested with fluconazole and itraconazole matched the NCCLS published values. However, considerable interlaboratory variability was seen in the results of the caspofungin tests. For Candida spp. the most consistent MIC data were generated with visual "prominent growth reduction" (MIC2) end points measured at 24 h in RPMI 1640, where 73.3% of results for the 30 isolates tested fell within a mode ± one dilution range across all 17 laboratories. MIC2 at 24 h in RPMI 1640 or AM3 also gave the best interlaboratory separation of Candida isolates of known high and low susceptibility to caspofungin. Reproducibility of MIC data was problematic for caspofungin tests with Aspergillus spp. under all conditions, but the minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories.


arrow
INTRODUCTION
 
Caspofungin acetate (Cancidas, formerly MK-0991 and L-743872; Merck & Co., Inc.) is an echinocandin-class antifungal agent, recently approved in the United States and Europe for the treatment of invasive aspergillosis that is refractory to other antifungal treatments, esophageal Candida infections and invasive Candida infections (11). Caspofungin inhibits synthesis of ß-1,3-D-glucan in fungal cell walls, a property that results in fungicidal effects against Candida species, in which this polysaccharide is vital to cell wall integrity (8).

Susceptibility tests of caspofungin against Candida species have been done according to the National Committee for Clinical Laboratory Standards (NCCLS) method M27-A (18) or its recent second edition M27-A2 (19), the reference protocol for testing azoles, flucytosine, and polyene antifungal agents against yeasts. Quality control (QC) limits have been established for caspofungin in M27-A tests with reference isolates of Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 (3). A European reference method (EUCAST) for antifungal susceptibility testing with Candida spp. gives results that closely match those obtained by method M27 for azole antifungals (6). The EUCAST method is very similar to M27-A2 but uses a higher yeast inoculum, a shorter incubation time, flat-bottom microdilution plates, and spectrophotometric end point determinations (6).

Published caspofungin MICs for Candida species suggest interlaboratory variation in the ranges of caspofungin MICs determined by NCCLS method M27-A. For example, whereas some authors found caspofungin MIC ranges against isolates of C. albicans from 0.03 to 1 µg/ml (12, 14, 16, 21, 23, 26), other researchers have reported higher ranges of 0.25 to 4 µg/ml (5, 9, 15). For tests with C. tropicalis, the highest caspofungin MIC from some laboratories (14, 16) was at or below the lowest MIC reported from others (5, 9, 15, 21). Differences of this order may represent intrinsic differences in the susceptibility of the panels of isolates tested, or they may indicate interlaboratory disparities in susceptibility tests with caspofungin.

For Aspergillus species, agreement in published MICs is unimpressive. For filamentous fungi, the NCCLS reference method is M38-A, approved for tests with azoles, flucytosine, and polyenes (17). For 26 A. fumigatus isolates, Arikan et al. reported geometric mean MICs of caspofungin of 0.43 µg/ml after 24 h of incubation and of >16 µg/ml after 72 h of incubation (1). By comparison, 72-h geometric mean MICs versus A. fumigatus were determined to be 2.15 µg/ml by Espinel-Ingroff (9) by using method M38-A and ≤0.09 µg/ml by Del Poeta et al. (7), who used a tube dilution method. Pfaller et al. (22) reported 72-h caspofungin MICs of 0.06 and 0.12 µg/ml for 12 isolates of A. fumigatus. In all of these studies the growth medium used was RPMI 1640 buffered with morpholinepropanesulfonic acid according to NCCLS M38-A recommendations (17). The minimum effective concentration (MEC), defined as the lowest caspofungin concentration that results in growth of A. fumigatus producing conspicuously aberrant hyphae, has been found to generate more consistent susceptibility data than the MIC (1, 9, 10).

Alterations in the growth medium, pH, incubation temperature, and inoculum size were found to cause caspofungin MIC variations in microdilution tests (4) but not in macrodilution tests (12). Most investigators have found that caspofungin MICs against all fungal types are lower when determined in Antibiotic Medium 3 (AM3) than in RPMI 1640 medium (2, 4, 20, 23).

To provide a prospective evaluation of interlaboratory agreement with caspofungin susceptibility tests, 17 laboratories collaborated to test 30 isolates of Candida spp. and 20 isolates of Aspergillus spp. under a variety of different conditions. The laboratories were located in the United States, Canada, Europe, and Australia. The test plates and growth media were supplied from a central source. The MIC and MEC end points were determined by visual inspection, and MICs were additionally determined from spectrophotometric data.


arrow
MATERIALS AND METHODS
 
Fungi. A panel of 30 isolates of Candida spp. and 20 Aspergillus spp. (Table 1) was assembled by Merck Research Laboratories (Rahway, N.J.). A blinded code number was assigned to each isolate, and the panels of fungi were distributed to the 17 participating laboratories. C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 were included among the 30 yeast isolates as NCCLS-recommended QC strains for antifungal susceptibility testing by method M27-A2 (19). A. flavus ATCC 204304 and A. fumigatus ATCC 204305 were included among the 20 mould isolates as reference strains for testing by method M38-A (17). The panel of yeast isolates also contained two strains known to be heterozygous for a mutation in the FKS1 gene, the caspofungin target, and six strains known to be homozygous for mutations in FKS1 (8). All eight of these yeasts have reduced susceptibility to caspofungin in vitro; the two heterozygous mutants less so than the six homozygous mutants.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Details of the panel of fungi tested in this studya

For all isolates, inocula of yeasts and Aspergillus conidia were prepared by standard methods (17, 19) and diluted appropriately to the specified initial concentrations. The growth media and 96-well microdilution plates containing antifungal agents were prepared by a commercial supplier (Trek Diagnostic Systems, Inc., Cleveland, Ohio). The media used in the tests were morpholinepropanesulfonic acid-buffered RPMI 1640 (RPMI) (17, 19), RPMI 1640 with a 2% glucose concentration instead of the usual 0.2% (RP-G), and AM3.

Experimental design. For the 30 Candida spp. isolates, duplicate plates were set up with caspofungin dilutions from 32 to 0.032 µg/ml tested in RPMI and RP-G with starting yeast concentrations of 1 to 5 x 103 CFU/ml and in RP-G with a starting yeast concentration of 1 x 105 to 5 x 105 CFU/ml. For tests in AM3, the caspofungin dilution range was 8 to 0.008 µg/ml, and the initial yeast concentration was 103 CFU/ml. As a reference standard, fluconazole dilutions from 64 to 0.063 µg/ml were tested in RPMI with an initial yeast concentration of 103 CFU/ml (19).

Inoculated microplates were incubated at 35°C in a humid environment. After 24 h the plates were carefully shaken to distribute yeast growth evenly, and the MICs of caspofungin for Candida spp. were recorded according to two visual criteria: MIC0, the lowest caspofungin concentration that supported no visible growth (a clear well), and MIC2, the lowest caspofungin concentration that caused a significant diminution of growth below control growth levels (19). Each lab then used a microplate spectrophotometer to determine the turbidity (optical density [OD]) of each well at 530 to 500 nm. For each of the three growth media tested, one caspofungin plate was set up with uninoculated medium for determination of the mean background OD values. These values were subtracted from the experimental OD values, and two MIC end points were determined from the spectrophotometric data: IC50, the lowest caspofungin concentration that reduced turbidity to <50% of the mean control turbidity, and IC90, the lowest caspofungin concentration that reduced turbidity to <90% of the control.

For the 20 Aspergillus spp. isolates, duplicate microdilution plates contained a caspofungin concentration series from 16 to 0.016 µg/ml, tested in RPMI, RP-G, and AM3, all inoculated to an initial concentration of 1 x 104 to 5 x 104 CFU/ml as recommended by the NCCLS for mold testing (17). Itraconazole concentrations from 8 to 0.008 µg/ml were also tested as a reference controls. Visual and spectrophotometric MIC and IC readings were made as for the Candida spp., except that the plates were not shaken before they were read. In addition, the caspofungin MEC was recorded at 24 h; this concentration was defined by reference to a photograph as the lowest that led to the growth of small, rounded, compact colonies compared to the florid hyphal growth seen in controls.

After 48 h of incubation, the MIC0, MIC2, IC90, and IC50 values were read for all fungi in the same way as at 24 h. After 48 h, MIC2 was read for fluconazole, and the MIC0 was read for itraconazole. The protocol also called for measurement of minimum fungicidal concentrations of caspofungin against Candida spp. at 48 h, but a high level of protocol violation in this test led to its being discounted for further analysis.

Analysis of data. All visually read susceptibility end points were typed into standardized result spreadsheets, and all spectrophotometric data were pasted into a standardized analysis template distributed to all participants. MIC and IC values that were off-scale were recorded as the lowest test concentration when all wells showed growth inhibition and as the next-highest concentration above the highest in a series when no well reached the end point being tested.

For each test condition the minimum, maximum, and modal MIC or IC value was determined. For each isolate tested, the number and percentage of results within ±1 dilution of the modal MIC or IC value was determined. "Excellent agreement" was defined as ≥90% of results or more within the mode ± one dilution range. "Moderate agreement" was defined as ≥80% of results within the mode ± one dilution range.


arrow
RESULTS
 
Data returns, technical problems, and protocol violations. All 17 participating laboratories, designated A through Q here, returned data spreadsheets. The visually read MICs were complete according to protocol for all 17 laboratories, with the sole exception of laboratory P, which provided no caspofungin MEC readings for molds tested in RP-G and AM3. For the spectrophotometric data, the results from laboratory K contained many omissions and inexplicable inaccuracies and were rejected from analysis. Laboratory F provided spectrophotometric results only for one of each of the duplicate plates set up with Candida spp. and no spectrophotometric data for the Aspergillus spp.

Two complaints of technical problems arose commonly among the participants. One was of yeast isolates where growth was inhibited in wells in the central portion of the dilution series but returned at the two or three highest concentrations (spectrophotometric data verified that regrowth at the highest test concentrations occurred often for some of the isolates tested [see below]). The second was of the appearance of air bubbles in the plates, which hampered the reading of end points, particularly by spectrophotometry. In some laboratories that experienced air bubble formation in the plates the plates were centrifuged to disperse bubbles before they were read. Where participants felt unable to judge a visual MIC end point (commonly because of inadequate control growth), the result was recorded as a blank for purposes of analysis.

Intralaboratory data agreement. With very few exceptions, the results showed excellent agreement for duplicate results obtained within each laboratory. For the 30 yeast isolates across 17 laboratories, 1.8 to 3.6% of the results showed intralaboratory differences beyond one twofold dilution, depending on the test conditions; these percentages were calculated from >1,000 data per test condition. For the 20 mold isolates across the 17 laboratories, 0.0 to 5.1% of results showed intralaboratory differences beyond one twofold dilution.

Fluconazole MICs for Candida spp. For QC strain C. krusei ATCC 6258, the current fluconazole QC limits according to the NCCLS are 16 to 128 µg/ml (19). From the 17 participating laboratories, the fluconazole modal MIC for this strain was 32 µg/ml, and all laboratories reported this value or 16 or 64 µg/ml, which is in perfect agreement with the reference MIC range. For QC strain C. parapsilosis ATCC 22019 the reference fluconazole MIC range is 1.0 to 4.0 µg/ml (19). In the present study the modal MIC for fluconazole was 2.0 µg/ml, and 30 of 33 (90.9%) of results fell within ±1 dilution of this mode and thus within the NCCLS specified limits. One laboratory reported duplicate off-range results of 8 µg/ml for ATCC 22019; however, exclusion of data from this laboratory had no effect on the results of the analyses of interlaboratory variation for fluconazole or caspofungin MICs.

Fluconazole modal MICs for the 30 Candida spp. isolates ranged from 0.13 to 32 µg/ml, showing that a full range of fluconazole susceptibilities was represented in the test panel. Across the 30 isolates, reproducibility within a three-dilution range varied from 62.9 to 100%. Excellent agreement was achieved for only 14 (47%) of the isolates, but moderate agreement was achieved for 25 (83%) of the isolates. Excellent agreement was less common (36.4% of 11 isolates) for C. albicans than for other Candida species (52.6% of 19 isolates), but this difference was not statistically significant ({chi}2 test).

Caspofungin MICs for Candida spp. Levels of agreement for MIC and IC values obtained with caspofungin for the 30 Candida isolates tested in 17 laboratories for all growth media, inoculum sizes, incubation times, and end points are summarized in Table 2. For visual readings, the interlaboratory reproducibility of the MIC estimates was poor under most of the test conditions. Excellent interlaboratory agreement was achieved for ≥60% of the isolates tested only for MIC2 in RPMI read at 24 h, MIC0 in RP-G with 105 cells/ml read at 48 h, and MIC2 in AM3 read at 24 h. Moderate agreement was achieved with visual end points for 93% of the Candida isolates with MIC2 read at 24 h in RPMI and for 77% of the isolates with MIC0 or MIC2 read at 24 h in AM3 (details not shown).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Interlaboratory agreement for caspofungin susceptibility data with 30 isolates of Candida spp.a

For the two QC isolates, excellent agreement with published MIC ranges (3) was achieved under NCCLS-recommended conditions (MIC2 read at 48 h in RPMI). For C. parapsilosis ATCC 22019 all data, except for a single result of 0.25 µg/ml fell in the QC range of 0.5 to 4.0 µg/ml (mode 1.0 µg/ml). For C. krusei ATCC 6258, 16 laboratories reported results within the QC range of 0.25 to 1.0 µg/ml (mode = 0.5 µg/ml), with one laboratory reporting 0.13 µg/ml.

Under many of the test conditions, the interlaboratory disparities in caspofungin visual MIC results for all 30 yeast isolates were considerable. MICs reported for some individual isolates included the high and low extremes of the concentration ranges tested. However, this effect was exacerbated by a minority of laboratories whose results occasionally differed substantially from those of the other participants. Scrutiny of the modal MICs for the panel of 30 Candida spp. isolates from each laboratory indicated outlying data (more than two dilutions higher or lower than the mode of values for all of the laboratories) under most test conditions. The results from four laboratories—C, D, F, and L—differed most often from the remainder by this assessment, but there was no consistent discrepancy, suggesting that data from any individual laboratories were persistently higher or lower than the rest to justify their exclusion from analysis.

The interlaboratory agreement for caspofungin IC50 and IC90 values determined from spectrophotometric data are also summarized in Table 2. When all data were included in the analysis the interlaboratory agreement for the spectrophotometric data was of a similar order as for visually read MICs. Excellent agreement for more than half of the test isolates was seen only in RPMI and in RP-G with the 103 yeasts/ml initial concentration.

Figure 1 illustrates typical characteristics of the dose-response curves obtained from spectrophotometric means of growth turbidity relative to control growth in caspofungin dilution series under different conditions. For C. albicans isolate Y102 after 24 h of incubation (Fig. 1a), the dose-response curves in RPMI and RP-G with 103 cells/ml were similar. For RP-G with the higher inoculum, the curve showed an inflexion at middle-range caspofungin concentrations and then fell to <20% of control at 32 µg/ml. The curve in AM3 indicated considerable growth inhibition at all caspofungin concentrations. Interlaboratory agreement was good after 24 h, with low standard errors of the mean at all caspofungin concentrations. For C. albicans Y106 after 48 h (Fig. 1b) the dose-response curves showed a nonsigmoid appearance. In all three RPMI 1640-based media the curves indicated growth inhibition to be <40% of the control with caspofungin at 4 µg/ml and then regrowth at higher concentrations. The curve in AM3 showed no regrowth of the yeast at high caspofungin concentrations.



View larger version (24K):
[in this window]
[in a new window]
  		FIG. 1. Dose-response curves for caspofungin growth inhibition constructed from individual spectrophotometric data presented by 16 laboratories. Curves show growth of a C. albicans isolate as mean percent control in the presence of a caspofungin concentration series, with error bars showing the standard error of the mean (n = 32). Cultures were in RPMI ({circ}), RP-G inoculated to 103/ml ({square}), RP-G inoculated to 105/ml ({blacktriangleup}), and AM3 (•). (a) Y102 after 24 h of incubation; (b) Y106 after 48 h of incubation.

Test conditions to distinguish Candida isolates of high and low caspofungin susceptibility. The panel of yeast isolates included eight yeasts known to have mutations in the FKS1 gene that result in lower than normal caspofungin susceptibility. To determine whether the conditions that gave highest interlaboratory test reproducibility for caspofungin MIC and IC values could also distinguish the two yeast susceptibility groups, the results obtained by MIC2 and IC50 in RPMI and AM3 after 24 h were analyzed (Table 3). The distribution of MIC results reported from the 17 laboratories for the isolates with normal and reduced caspofungin susceptibility were analyzed by the {chi}2 test. The larger the value of {chi}2 for each paired data set of high versus low susceptibility, the greater the differentiation between the susceptibility groups (all of the values in Table 4 showed a statistically significant difference in the MIC distributions for high- and low-susceptibility isolates). The results suggested that the visually determined MIC2 values discriminated better between the two groups than the spectrophotometrically determined IC50 values and that the data from tests in AM3 discriminated better than the data from tests in RPMI.


View this table:
[in this window]
[in a new window]
  		TABLE 3. Percentages of MIC2 or IC50 results recorded in 17 laboratories for 8 Candida spp. isolates with known low susceptibility to caspofungin and 22 isolates with normal susceptibility


View this table:
[in this window]
[in a new window]
  		TABLE 4. Interlaboratory agreement for caspofungin susceptibility data with 20 isolates of Aspergillus spp.a

Itraconazole MICs for Aspergillus spp. The itraconazole MICs for the panel of 20 Aspergillus spp. isolates tested in the 17 participating laboratories were read as the MIC0 after 48 h growth of the molds. The data varied only over a narrow range of values, from 0.13 to 1.0 µg/ml, with a modal MIC for most isolates of 0.5 µg/ml. For the two NCCLS reference isolates, A. flavus ATCC 204304 and A. fumigatus ATCC 204305, the modal itraconazole MICs of 0.50 and 1.0 µg/ml fell within the prescribed reference ranges for method M38-A (17). The percentage of data within the prescribed ranges was 90.9% (30 of 33 readings) and 100% for the two strains, respectively.

Caspofungin MICs for Aspergillus spp. Agreement between 17 laboratories for MIC and IC values of caspofungin for the 20 Aspergillus isolates for all growth media, inoculum sizes, incubation times, and end points is summarized in Table 4. The agreement between results obtained with the spectrophotometer was impossibly poor under all conditions. For the visually read end points, the best agreement was obtained (≥70% of isolates showing excellent agreement) for MIC0 readings at 24 and 48 h for all growth media. However, this is a misleading observation, since almost all of the isolates were scored as resistant to the highest concentration of caspofungin tested (MIC > 16 µg/ml) in terms of MIC0 in most laboratories, and agreement with so many off-scale data was to be expected. The interlaboratory agreement for the tests with Aspergillus spp. isolates was therefore interpreted as poor under all conditions. Spectrophotometric IC determinations with the molds were unhelpful with the Aspergillus spp. isolates.

Caspofungin MEC values for Aspergillus spp. Measurement of the 24-h MECs did not enhance the poor interlaboratory reproducibility of the Aspergillus susceptibility data; results tended to parallel those obtained with the MIC2 readings (Table 4). However, MEC data from laboratories E, H, and J tended to be much higher than those from other laboratories, suggesting possible problems with MEC readings from these three participants. Removal of these sets of data from the analysis improved the interlaboratory agreement under all three test conditions (Table 4). The percentage of 20 isolates for which excellent agreement was achieved rose from only 5 to 15%, with all results included, to 100, 75, and 85% in RPMI, RP-G, and AM3, respectively, with the data from laboratories E, H, and J omitted.

MEC results also produced the lowest susceptibility readings for the Aspergillus isolates. In RPMI, RP-G, and AM3, respectively, 93, 91, and 87% of the reported MECs were <1 µg/ml, rising to 100, 98, and 98%, respectively, when the results from laboratories E, H, and J were omitted.


arrow
DISCUSSION
 
This study involved analysis of more than 52,000 individual datum points determined from 17 laboratories located in North America, Europe, and Australasia and represents one of the most extensive surveys of methodology for susceptibility testing with an antifungal agent ever undertaken. The results provide reasons for both optimism and concern over susceptibility testing with caspofungin in vitro. We set our criterion for excellent reproducibility as a requirement for ≥90% of MIC or IC data for a single fungal isolate to be within a mode ± one dilution range. This matches the levels of agreement obtained in, for example, NCCLS QC studies with antifungal agents (3). It may be argued that the criterion is too stringent, but it represents the normally accepted standard.

A positive finding of our study is that two test conditions, MIC2 or IC50 read at 24 h for cultures in RPMI 1640 medium or AM3, gave excellent interlaboratory agreement for a majority of the panel of 30 isolates of Candida spp., both by visual and spectrophotometric end point determination. Under these conditions a high level of discrimination was achieved between strains known to have lowered caspofungin susceptibility and normally susceptible isolates. These conditions therefore emerge as strong contenders for refinement of methodology to give as-near-as-possible acceptable interlaboratory reproducibility for caspofungin testing—an obvious prerequisite before clinically relevant resistance breakpoints can be set for this new antifungal agent.

However, it is a matter of concern that the reproducibility in caspofungin susceptibility tests with isolates of Aspergillus spp. was of such a low order. Under all conditions tested, some growth of these molds occurred in the presence of all concentrations of caspofungin, so that a susceptibility test end point based on complete inhibition of growth is impractical, as has been observed previously (1, 10, 13). In contrast, an MIC end point based on "prominent growth reduction relative to control" (MIC2) gave results at the very low end of the caspofungin concentration range tested, suggesting a high susceptibility of Aspergillus spp. to this agent. However, even for MIC2 data, the proportion of isolates for which 90% of the results fell within the range of mode ± one dilution was unacceptably low. The MEC, an end point proposed in previous studies that also measures partial, rather than complete growth inhibition (1, 10, 13), greatly improved interlaboratory reproducibility over MIC readings in the present study when data from 3 of the 17 participating laboratories were excluded. The reason why three laboratories that would generally be regarded as experienced with antifungal susceptibility testing should produce aberrant data is unclear. The MEC end point requires some caution in its interpretation, as it represents a subjective assessment of the appearance of growth, but our findings generally confirm the utility of this end point for testing caspofungin against Aspergillus spp.

For both the Candida and the Aspergillus spp. tested, the data for fluconazole or itraconazole against QC and reference isolates fell almost perfectly within expected limits. This finding confirmed the competence of the 17 laboratories to undertake antifungal susceptibility testing. Although it was possible to define MEC data from 3 of 17 laboratories as unacceptably divergent, the same was not true for caspofungin MICs against Candida or Aspergillus spp., where apparently outlying data sets were typically seen as occasional idiosyncracies under just one of the conditions tested, rather than as consistently "maverick" results from one or more laboratories.

The results for tests with fluconazole versus Candida spp. gave a higher level of interlaboratory discordance than anticipated. These tests were done by the reference microdilution methodology prescribed by the NCCLS (19); yet, for 5 of the 30 isolates tested, fewer than 80% of the results from the 17 laboratories agreed within a mode ± one dilution range. A recent New York State proficiency testing study found an overall level of agreement with reference values of just 75% for fluconazole MICs determined in seven laboratories with five isolates of Candida spp. (24). No Candida isolate from an infected patient is routinely subjected to multiple-laboratory testing, and the possibility of over- or underestimation of susceptibility in a single laboratory test appears high enough to justify future attention.

Susceptibility testing with any microorganism is a procedure with a high level of inherent run-to-run variability, and any prescribed set of test conditions represents a compromise between choices of test variables. Some isolates of fungi seem to generate consistent MIC data regardless of variations in test conditions, whereas others show high vulnerability even to relatively minor variations (4, 25). The objective of the design of susceptibility test conditions should be to devise a methodology that is least affected by small differences in technical parameters. Our study shows that, for tests with caspofungin against Candida spp., the present NCCLS method M27-A gives reasonable interlaboratory reproducibility, provided MICs are read as MIC2 after 24 h of incubation. However, there is still room for improvement in the methodology to raise the level of interlaboratory agreement to a higher standard. For caspofungin testing with Aspergillus spp., the MEC currently offers an end point that can give generally reproducible results in many laboratories, but the finding of 3 laboratories of 17 generating aberrant data even by MEC suggests that further refinement of caspofungin test methodology for Aspergillus spp. is still required.


arrow
ACKNOWLEDGMENTS
 
This study was supported by a grant from Merck & Co., Inc.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Aberdeen Fungal Group, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, United Kingdom. Phone: (44) 1224-273128. Fax: (44) 1224-273144. E-mail: f.odds{at}abdn.ac.uk. Back

{dagger} Present address: AstraZeneca, Alderley Park, Manchester, United Kingdom. Back


arrow
REFERENCES
 
    1
  1. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2001. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. 45:327-330.[Abstract/Free Full Text]
    2. 2
  2. Arikan, S., M. Lozano-Chiu, V. Paetznick, and J. H. Rex. 2002. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. 46:245-247.[Abstract/Free Full Text]
    3. 3
  3. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.[Abstract/Free Full Text]
    4. 4
  4. Bartizal, C., and F. C. Odds. 2003. Influence of methodologic variables on susceptibility testing with caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:2100-2107.[Abstract/Free Full Text]
    5. 5
  5. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.[Abstract]
    6. 6
  6. Cuenca-Estrella, M., W. Lee-Yang, M. A. Ciblak, B. A. Arthington-Skaggs, E. Mellado, D. W. Warnock, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647.[Abstract/Free Full Text]
    7. 7
  7. Del Poeta, M., W. A. Schell, and J. R. Perfect. 1997. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41:1835-1836.[Abstract]
    8. 8
  8. Douglas, C. M., J. A. Dippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the fks1 gene of Candida albicans as the essential target of 1,3-ß-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.[Abstract]
    9. 9
  9. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole Sch56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.[Abstract/Free Full Text]
    10. 10
  10. Espinel-Ingroff, A. 2003. Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991). J. Clin. Microbiol. 41:403-409.[Abstract/Free Full Text]
    11. 11
  11. Keating, G. M., and B. Jarvis. 2001. Caspofungin. Drugs 61:1121-1129.[CrossRef][Medline]
    12. 12
  12. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.[Abstract]
    13. 13
  13. Kurtz, M. B., G. Abruzzo, K. Bartizal, J. A. Marrinan, W. Li, J. Milligan, K. Nollstadt, and C. M. Douglas. 1996. Characterization of echinocardin-resistant mutants of Candida albicans—genetic, biochemical, and virulence studies. Infect. Immun. 64:3244-3251.[Abstract]
    14. 14
  14. Laverdiere, M., C. Restieri, and F. Habel. 2002. Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods. Int. J. Antimicrob. Agents 20:468-471.[CrossRef][Medline]
    15. 15
  15. Lozano-Chiu, M., P. W. Nelson, V. L. Paetznick, and J. H. Rex. 1999. Disk diffusion method for determining susceptibilities of Candida spp. to MK-0991. J. Clin. Microbiol. 37:1625-1627.[Abstract/Free Full Text]
    16. 16
  16. Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. 1998. Activity of MK-0991 (L-743,872), a new echinocandin, compared to those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 32:33-37.[CrossRef][Medline]
    17. 17
  17. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. NCCLS, Wayne, Pa.
    18. 18
  18. NCCLS. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    19. 19
  19. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. NCCLS, Wayne, Pa.
    20. 20
  20. Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1997. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J. Med. Vet. Mycol. 35:285-287.[Medline]
    21. 21
  21. Pfaller, M. A., R. N. Jones, G. V. Doern, A. C. Fluit, J. Verhoef, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, and R. J. Hollis. 1999. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35:19-25.[CrossRef][Medline]
    22. 22
  22. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.[CrossRef][Medline]
    23. 23
  23. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmstrom, and R. N. Jones. 2001. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. 39:4387-4389.[Abstract/Free Full Text]
    24. 24
  24. Ramani, R., and V. Chaturvedi. 2003. Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species. J. Clin. Microbiol. 41:1143-1146.[Abstract/Free Full Text]
    25. 25
  25. Rambali, B., J. A. Fernandez, L. Van Nuffel, F. Woestenborghs, L. Baert, D. L. Massart, and F. C. Odds. 2001. Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. J. Antimicrob. Chemother. 48:163-177.[Abstract/Free Full Text]
    26. 26
  26. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.[Abstract]

Journal of Clinical Microbiology, August 2004, p. 3475-3482, Vol. 42, No. 8
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.8.3475-3482.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kauffman, C. A., Kontoyiannis, D. P., Ito, J. I., Balajee, S. A., Pappas, P. G., Moser, S. A. (2009). Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47: 3271-3275 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2009). In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method. J. Clin. Microbiol. 47: 3323-3325 [Abstract] [Full Text]  
  • Spreghini, E., Orlando, F., Santinelli, A., Pisa, E., Loretelli, C., Manso, E., Milici, M. E., Scalise, G., Barchiesi, F. (2009). Anidulafungin in Combination with Amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother. 53: 4035-4039 [Abstract] [Full Text]  
  • Canton, E., Peman, J., Valentin, A., Espinel-Ingroff, A., Gobernado, M. (2009). In Vitro Activities of Echinocandins against Candida krusei Determined by Three Methods: MIC and Minimal Fungicidal Concentration Measurements and Time-Kill Studies. Antimicrob. Agents Chemother. 53: 3108-3111 [Abstract] [Full Text]  
  • Messer, S. A., Moet, G. J., Kirby, J. T., Jones, R. N. (2009). Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 47: 1942-1946 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Monzon, A., Buitrago, M. J., Rodriguez-Tudela, J. L. (2009). Activity Profile In Vitro of Micafungin against Spanish Clinical Isolates of Common and Emerging Species of Yeasts and Molds. Antimicrob. Agents Chemother. 53: 2192-2195 [Abstract] [Full Text]  
  • Lass-Florl, C., Alastruey-Izquierdo, A., Cuenca-Estrella, M., Perkhofer, S., Rodriguez-Tudela, J. L. (2009). In Vitro Activities of Various Antifungal Drugs against Aspergillus terreus: Global Assessment Using the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53: 794-795 [Abstract] [Full Text]  
  • Maida, C. M., Milici, M. E., Trovato, L., Oliveri, S., Amodio, E., Spreghini, E., Scalise, G., Barchiesi, F. (2008). Evaluation of the Disk Diffusion Method Compared to the Microdilution Method in Susceptibility Testing of Anidulafungin against Filamentous Fungi. J. Clin. Microbiol. 46: 4071-4074 [Abstract] [Full Text]  
  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Lass-Florl, C., Mayr, A., Perkhofer, S., Hinterberger, G., Hausdorfer, J., Speth, C., Fille, M. (2008). Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3637-3641 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., Dannaoui, E. (2008). Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098 [Abstract] [Full Text]  
  • Richards, T. S., Oliver, B. G., White, T. C. (2008). Micafungin activity against Candida albicans with diverse azole resistance phenotypes. J Antimicrob Chemother 62: 349-355 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Pfaller, M. A., Diekema, D. J. (2008). Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis. J. Clin. Microbiol. 46: 2659-2664 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]  
  • Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., Perlin, D. S. (2008). A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility. Antimicrob. Agents Chemother. 52: 2305-2312 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Dromer, F., Dannaoui, E. (2008). Detection of Caspofungin Resistance in Candida spp. by Etest. J. Clin. Microbiol. 46: 2389-2392 [Abstract] [Full Text]  
  • Pfaller, M. A., Chaturvedi, V., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., Ramani, R. (2008). Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin. J. Clin. Microbiol. 46: 2155-2159 [Abstract] [Full Text]  
  • Spreghini, E., Maida, C. M., Tomassetti, S., Orlando, F., Giannini, D., Milici, M. E., Scalise, G., Barchiesi, F. (2008). Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole. Antimicrob. Agents Chemother. 52: 1929-1933 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Canton, E. (2008). Comparison of Neo-Sensitabs Tablet Diffusion Assay with CLSI Broth Microdilution M38-A and Disk Diffusion Methods for Testing Susceptibility of Filamentous Fungi with Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole. J. Clin. Microbiol. 46: 1793-1803 [Abstract] [Full Text]  
  • Spreghini, E., Maida, C. M., Milici, M. E., Scalise, G., Barchiesi, F. (2008). Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B. Antimicrob. Agents Chemother. 52: 513-517 [Abstract] [Full Text]  
  • Dannaoui, E., Lortholary, O., Raoux, D., Bougnoux, M. E., Galeazzi, G., Lawrence, C., Moissenet, D., Poilane, I., Hoinard, D., Dromer, F., and the YEASTS Group, (2008). Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006. Antimicrob. Agents Chemother. 52: 778-781 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., Walsh, T. J. (2008). Comparative In Vitro Pharmacodynamics of Caspofungin, Micafungin, and Anidulafungin against Germinated and Nongerminated Aspergillus Conidia. Antimicrob. Agents Chemother. 52: 321-328 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Pfaller, M. A., Diekema, D. J. (2008). Lodderomyces elongisporus Masquerading as Candida parapsilosis as a Cause of Bloodstream Infections. J. Clin. Microbiol. 46: 374-376 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2008). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J. Clin. Microbiol. 46: 150-156 [Abstract] [Full Text]  
  • Johnson, E. M. (2008). Issues in antifungal susceptibility testing. J Antimicrob Chemother 61: i13-i18 [Abstract] [Full Text]  
  • Milici, M. E., Maida, C. M., Spreghini, E., Ravazzolo, B., Oliveri, S., Scalise, G., Barchiesi, F. (2007). Comparison between Disk Diffusion and Microdilution Methods for Determining Susceptibility of Clinical Fungal Isolates to Caspofungin. J. Clin. Microbiol. 45: 3529-3533 [Abstract] [Full Text]  
  • Plummer, R., Bodkin, J., Power, D., Pantarat, N., Bubb, W. A., Kuchel, P. W., Sorrell, T. C. (2007). Effect of Caspofungin on Metabolite Profiles of Aspergillus Species Determined by Nuclear Magnetic Resonance Spectroscopy. Antimicrob. Agents Chemother. 51: 4077-4084 [Abstract] [Full Text]  
  • Chauhan, N., Kruppa, M., Calderone, R. (2007). The Ssk1p Response Regulator and Chk1p Histidine Kinase Mutants of Candida albicans Are Hypersensitive to Fluconazole and Voriconazole. Antimicrob. Agents Chemother. 51: 3747-3751 [Abstract] [Full Text]  
  • Zepelin, M. B.-v., Kunz, L., Ruchel, R., Reichard, U., Weig, M., Gross, U. (2007). Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 60: 424-428 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Fothergill, A., Ghannoum, M., Manavathu, E., Ostrosky-Zeichner, L., Pfaller, M. A., Rinaldi, M. G., Schell, W., Walsh, T. J. (2007). Quality Control and Reference Guidelines for CLSI Broth Microdilution Method (M38-A Document) for Susceptibility Testing of Anidulafungin against Molds. J. Clin. Microbiol. 45: 2180-2182 [Abstract] [Full Text]  
  • Perumal, P., Mekala, S., Chaffin, W. L. (2007). Role for Cell Density in Antifungal Drug Resistance in Candida albicans Biofilms. Antimicrob. Agents Chemother. 51: 2454-2463 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Arthington-Skaggs, B., Iqbal, N., Ellis, D., Pfaller, M. A., Messer, S., Rinaldi, M., Fothergill, A., Gibbs, D. L., Wang, A. (2007). Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin. J. Clin. Microbiol. 45: 1811-1820 [Abstract] [Full Text]  
  • Baixench, M.-T., Aoun, N., Desnos-Ollivier, M., Garcia-Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., Dannaoui, E. (2007). Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59: 1076-1083 [Abstract] [Full Text]  
  • Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M., Graybill, J. R. (2007). In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera. Antimicrob. Agents Chemother. 51: 1616-1620 [Abstract] [Full Text]  
  • Jacobsen, M. D., Whyte, J. A., Odds, F. C. (2007). Candida albicans and Candida dubliniensis Respond Differently to Echinocandin Antifungal Agents In Vitro. Antimicrob. Agents Chemother. 51: 1882-1884 [Abstract] [Full Text]  
  • da Matta, V. L. R., Melhem, M. d. S. C., Colombo, A. L., Moretti, M. L., Rodero, L., de Almeida, G. M. D., Martins, M. d. A., Costa, S. F., Souza Dias, M. B. G., Nucci, M., Levin, A. S. (2007). Antifungal Drug Susceptibility Profile of Pichia anomala Isolates from Patients Presenting with Nosocomial Fungemia. Antimicrob. Agents Chemother. 51: 1573-1576 [Abstract] [Full Text]  
  • Choi, H. W., Shin, J. H., Jung, S. I., Park, K. H., Cho, D., Kee, S. J., Shin, M. G., Suh, S. P., Ryang, D. W. (2007). Species-Specific Differences in the Susceptibilities of Biofilms Formed by Candida Bloodstream Isolates to Echinocandin Antifungals. Antimicrob. Agents Chemother. 51: 1520-1523 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., Walsh, T. J. (2007). Concentration-Dependent Effects of Caspofungin on the Metabolic Activity of Aspergillus Species. Antimicrob. Agents Chemother. 51: 881-887 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Tomassetti, S., Giannini, D., Scalise, G. (2007). Caspofungin in Combination with Amphotericin B against Candida parapsilosis. Antimicrob. Agents Chemother. 51: 941-945 [Abstract] [Full Text]  
  • Alexander, B. D., Byrne, T. C., Smith, K. L., Hanson, K. E., Anstrom, K. J., Perfect, J. R., Reller, L. B. (2007). Comparative Evaluation of Etest and Sensititre YeastOne Panels against the Clinical and Laboratory Standards Institute M27-A2 Reference Broth Microdilution Method for Testing Candida Susceptibility to Seven Antifungal Agents. J. Clin. Microbiol. 45: 698-706 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Canton, E., Gibbs, D., Wang, A. (2007). Correlation of Neo-Sensitabs Tablet Diffusion Assay Results on Three Different Agar Media with CLSI Broth Microdilution M27-A2 and Disk Diffusion M44-A Results for Testing Susceptibilities of Candida spp. and Cryptococcus neoformans to Amphotericin B, Caspofungin, Fluconazole, Itraconazole, and Voriconazole. J. Clin. Microbiol. 45: 858-864 [Abstract] [Full Text]  
  • Lee, J. S., Shin, J. H., Kim, M.-N., Jung, S.-I., Park, K. H., Cho, D., Kee, S. J., Shin, M. G., Suh, S. P., Ryang, D. W. (2007). Kodamaea ohmeri Isolates from Patients in a University Hospital: Identification, Antifungal Susceptibility, and Pulsed-Field Gel Electrophoresis Analysis. J. Clin. Microbiol. 45: 1005-1010 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Coen, M., Bodkin, J., Power, D., Bubb, W. A., Himmelreich, U., Kuchel, P. W., Sorrell, T. C. (2006). Antifungal Effects on Metabolite Profiles of Medically Important Yeast Species Measured by Nuclear Magnetic Resonance Spectroscopy. Antimicrob. Agents Chemother. 50: 4018-4026 [Abstract] [Full Text]  
  • Cota, J., Carden, M., Graybill, J. R., Najvar, L. K., Burgess, D. S., Wiederhold, N. P. (2006). In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility. Antimicrob. Agents Chemother. 50: 3926-3928 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods.. J. Clin. Microbiol. 44: 3533-3538 [Abstract] [Full Text]  
  • Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 2.. Am J Health Syst Pharm 63: 1813-1820 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., Scalise, G. (2006). Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis.. Antimicrob. Agents Chemother. 50: 2719-2727 [Abstract] [Full Text]  
  • Hakki, M., Staab, J. F., Marr, K. A. (2006). Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy.. Antimicrob. Agents Chemother. 50: 2522-2524 [Abstract] [Full Text]  
  • Clancy, C. J., Huang, H., Cheng, S., Derendorf, H., Nguyen, M. H. (2006). Characterizing the Effects of Caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata Isolates by Simultaneous Time-Kill and Postantifungal-Effect Experiments.. Antimicrob. Agents Chemother. 50: 2569-2572 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., Rodriguez-Tudela, J. L. (2006). Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrob. Agents Chemother. 50: 917-921 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance.. J. Clin. Microbiol. 44: 760-763 [Abstract] [Full Text]  
  • Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2006). Inhibition of Candida parapsilosis Mitochondrial Respiratory Pathways Enhances Susceptibility to Caspofungin. Antimicrob. Agents Chemother. 50: 744-747 [Abstract] [Full Text]  
  • Messer, S. A., Diekema, D. J., Boyken, L., Tendolkar, S., Hollis, R. J., Pfaller, M. A. (2006). Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp.. J. Clin. Microbiol. 44: 324-326 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Tomassetti, S., Arzeni, D., Giannini, D., Scalise, G. (2005). Comparison of the Fungicidal Activities of Caspofungin and Amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49: 4989-4992 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole. J. Clin. Microbiol. 43: 5425-5427 [Abstract] [Full Text]  
  • Kartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., Motyl, M. (2005). Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome. Antimicrob. Agents Chemother. 49: 3616-3623 [Abstract] [Full Text]  
  • MacCallum, D. M., Whyte, J. A., Odds, F. C. (2005). Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis. Antimicrob. Agents Chemother. 49: 3697-3701 [Abstract] [Full Text]  
  • Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T., Elsayed, S. (2005). Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 56: 532-537 [Abstract] [Full Text]  
  • Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  
  • Peter, J., Armstrong, D., Lyman, C. A., Walsh, T. J. (2005). Use of Fluorescent Probes To Determine MICs of Amphotericin B and Caspofungin against Candida spp. and Aspergillus spp.. J. Clin. Microbiol. 43: 3788-3792 [Abstract] [Full Text]  
  • Mitchell, M., Hudspeth, M., Wright, A. (2005). Flow Cytometry Susceptibility Testing for the Antifungal Caspofungin. J. Clin. Microbiol. 43: 2586-2589 [Abstract] [Full Text]  
  • Canton, E., Peman, J., Gobernado, M., Alvarez, E., Baquero, F., Cisterna, R., Gil, J., Martin-Mazuelos, E., Rubio, C., Sanchez-Sousa, A., Serrano, C. (2005). Sensititre YeastOne Caspofungin Susceptibility Testing of Candida Clinical Isolates: Correlation with Results of NCCLS M27-A2 Multicenter Study. Antimicrob. Agents Chemother. 49: 1604-1607 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Rodriguez, D., Almirante, B., Morgan, J., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J., Gimenez, M., Salvado, M., Warnock, D. W., Pahissa, A., Rodriguez-Tudela, J. L., on behalf of the Barcelona Candidemia Project Stud, (2005). In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 55: 194-199 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Odds, F. C.
Right arrow Articles by Warnock, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odds, F. C.
Right arrow Articles by Warnock, D. W.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»